206 related articles for article (PubMed ID: 16302103)
21. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
22. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
23. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
[TBL] [Abstract][Full Text] [Related]
25. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Chulay JD; Fleckenstein L; Smith DH
Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
[TBL] [Abstract][Full Text] [Related]
27. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
28. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M
Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789
[TBL] [Abstract][Full Text] [Related]
29. Effects of therapy on haemostasis in dogs infected with Leishmania infantum, Ehrlichia canis, or both combined.
Cortese L; Pelagalli A; Piantedosi D; Cestaro A; Di Loria A; Lombardi P; Avallone L; Ciaramella P
Vet Rec; 2009 Apr; 164(14):433-4. PubMed ID: 19346544
[No Abstract] [Full Text] [Related]
30. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
31. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
[TBL] [Abstract][Full Text] [Related]
32. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510
[No Abstract] [Full Text] [Related]
33. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
[TBL] [Abstract][Full Text] [Related]
34. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial.
Slappendel RJ; Teske E
Vet Q; 1997 Mar; 19(1):10-3. PubMed ID: 9225422
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of clinical and laboratory findings of adult visceral leishmaniasis cases].
Ural S; Kaptan F; Sezak N; El S; Örmen B; Türker N; Demirdal T; Vardar İ; Özkan Çayıröz P; Çakalağaoğlu F
Mikrobiyol Bul; 2015 Oct; 49(4):586-93. PubMed ID: 26649416
[TBL] [Abstract][Full Text] [Related]
36. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis.
Luciani A; Sconza S; Civitella C; Guglielmini C
Vet J; 2013 Apr; 196(1):119-21. PubMed ID: 23021954
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM
Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
Marsden PD
Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
[No Abstract] [Full Text] [Related]
40. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
